Our thinking on the state of clinical trials, the realities of site management, and how the industry can move past 30-year-old monitoring models.
The industry has accepted that high turnover, constant handoffs, and calendar-based visits are just the cost of doing business. They aren't. They are symptoms of an architectural flaw in how we define monitoring — and why the answer isn't better CRAs, it's a fundamentally different model.
Read the articleSuccess in a clinical trial isn't just about clean data. It's about publications, podium presentations, and regulatory milestones. Why the relationships your site team builds today determine your outcomes tomorrow.
How to move from passive metric reporting to active, data-driven site interventions — and why the difference between a report and an action is the most important gap in clinical monitoring today.
Rare disease trials require a fundamentally different approach to investigator support, patient retention, and clinical oversight. What the standard monitoring model gets wrong — and what it costs.
How the COL model eliminates the communication lag between central labs, specialty vendors, and clinical sites — and why the traditional escalation chain is one of the most underestimated sources of trial delay.
The sites that fail inspections aren't the ones that didn't prepare — they're the ones that prepared too late. What proactive TMF management and ongoing compliance oversight actually look like in practice.
Tell us about your study and we'll show you how our approach translates into execution at your sites.